Alumis Inc

This study is checking if a medication called ESK-001 is safe and keeps working for people with moderate-to-severe plaque psoriasis over a long period. It involves 1,680 adults who have already taken ESK-001 in a previous study. The research will see if the drug's benefits last a…

This large, late-stage study is testing whether a daily pill called ESK-001 can safely reduce the severity of moderate-to-severe plaque psoriasis. It will compare ESK-001 against a placebo (dummy pill) and an already-approved psoriasis medication called apremilast. About 840 adul…

This study follows patients who have already tried the experimental drug ESK-001 in a previous trial. It aims to see how safe and effective the drug is when taken for a longer period of time to control plaque psoriasis. About 165 participants will continue taking one of two doses…

This large Phase 3 study is testing whether a new oral medication called ESK-001 can safely reduce the severity of moderate-to-severe plaque psoriasis. It will compare ESK-001 against a placebo (dummy pill) and an approved psoriasis drug (apremilast) in 840 adults over 24 weeks. …